Trial · NCT00880997

The Efficacy of Doxazosin for Cocaine Users

NCT00880997, Phase 1, Completed, Baylor College of Medicine; results first posted 2019-08-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. The Efficacy of Doxazosin for Cocaine Users. Trials, record NCT00880997. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00880997

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Efficacy of Doxazosin for Cocaine Users
NCT number: NCT00880997
Status: Completed
Phases: Phase 1
Enrollment: 35 participants, actual
Lead sponsor: Baylor College of Medicine
Conditions: Cocaine Dependence
Interventions: Doxazosin, Placebo
First posted: 2009-04-14
Last updated: 2019-08-22
Results first posted: 2019-08-22
Limitations and caveats: Initially the study randomized subjects into 2 conditions (placebo/DOX). After the observation that rapid titration was safe, a DOX-fast group was created. This did not allow for early participants to be randomized to the rapid titration condition.

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Cocaine Negative Urines	throughout the study - up to 17 weeks	cocaine urine toxicology samples were obtained thrice weekly and tested for the presence of the cocaine metabolite, benzoylecgonine
Secondary	Weeks of Abstinence	throughout the study - up to 17 weeks	Percentage of participants achieving 2 or more consecutive weeks of abstinence
Secondary	# of Participants That Completed the Study	throughout the study - up to 17 weeks	Retention
Secondary	Adverse Events	throughout study - upto 17 weeks

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Cocaine Negative Urines	throughout the study - up to 17 weeks	percentage of cocaine-negative urines	NUMBER
SECONDARY	Weeks of Abstinence	throughout the study - up to 17 weeks	percentage of participants	NUMBER
SECONDARY	# of Participants That Completed the Study	throughout the study - up to 17 weeks	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Adverse Events	throughout study - upto 17 weeks	events	NUMBER

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Cocaine Negative Urines	DOX-slow Group	10	percentage of cocaine-negative urines
Cocaine Negative Urines	DOX-fast Group	35	percentage of cocaine-negative urines
Cocaine Negative Urines	Placebo	14	percentage of cocaine-negative urines
Weeks of Abstinence	DOX-slow Group	0	percentage of participants
Weeks of Abstinence	DOX-fast Group	44	percentage of participants
Weeks of Abstinence	Placebo	7	percentage of participants
# of Participants That Completed the Study	DOX-slow Group	6	Participants
# of Participants That Completed the Study	DOX-fast Group	6	Participants
# of Participants That Completed the Study	Placebo	5	Participants
Adverse Events	DOX-slow Group	26	events

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Doxazosin Fast	9
Overall Study	STARTED	Doxazosin Slow	8
Overall Study	STARTED	Placebo	13
Overall Study	COMPLETED	Doxazosin Fast	6
Overall Study	COMPLETED	Doxazosin Slow	6
Overall Study	COMPLETED	Placebo	5
Overall Study	NOT COMPLETED	Doxazosin Fast	3
Overall Study	NOT COMPLETED	Doxazosin Slow	2
Overall Study	NOT COMPLETED	Placebo	8

Source ClinicalTrials.gov

Adverse events9

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Headaches	Nervous system disorders	Dox-Slow Group	2	8
other	Headaches	Nervous system disorders	Dox-Fast Group:	1	9
other	Headaches	Nervous system disorders	Placebo	3	13
other	Dizinness	Cardiac disorders	Dox-Slow Group	0	8
other	Dizinness	Cardiac disorders	Dox-Fast Group:	2	9
other	Dizinness	Cardiac disorders	Placebo	0	13
other	Toothache	General disorders	Dox-Slow Group	1	8
other	Toothache	General disorders	Dox-Fast Group:	1	9
other	Toothache	General disorders	Placebo	0	13

Source ClinicalTrials.gov

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Dox-Slow Group	0	8
Total, all-cause mortality	Dox-Fast Group:	0	9
Total, all-cause mortality	Placebo	0	13
Total, other adverse events	Dox-Slow Group	2	8
Total, other adverse events	Dox-Fast Group:	3	9
Total, other adverse events	Placebo	3	13
Total, serious adverse events	Dox-Slow Group	0	8
Total, serious adverse events	Dox-Fast Group:	0	9
Total, serious adverse events	Placebo	0	13

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P50DA018197	Stimulant Pharmacotherapy: Noradrenergic Targets	KOSTEN, THOMAS RICHARD	BAYLOR COLLEGE OF MEDICINE	NATIONAL INSTITUTE ON DRUG ABUSE	2004 to 2013

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00880997

GET https://conductscience.org/api/trials/v1/NCT00880997/registered

API reference For AI assistants